Source:http://linkedlifedata.com/resource/pubmed/id/17657816
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2007-11-5
|
| pubmed:abstractText |
We showed previously that amino acid (aa) substitutions in hepatitis C virus core region (HCV-CR) are negative predictors of virologic response to pegylated interferon (IFN) plus ribavirin therapy. HCV-CR induces hepatocellular carcinoma in transgenic mice, but the clinical impact is still unclear. To evaluate the impact of aa substitutions in HCV-CR on hepatocarcinogenesis, we performed a follow-up study on 313 noncirrhotic consecutive naïve patients infected with HCV genotype 1b who received IFN monotherapy. The median follow-up was 14.7 years. A sustained virologic response (SVR) after the first IFN was achieved by 65 patients (20.8%) (group A). Of 248 patients (79.2%) of non-SVR after first IFN, 112 (35.8%) did not receive additional IFN (group B), and the remaining 136 (43.5%) received multicourse IFN monotherapy (group C). As a whole, cumulative hepatocarcinogenesis rates in double wild-type (arginine at aa 70/leucine at aa 91) of HCV-CR were significantly lower than those in nondouble wild-type. Multivariate analyses identified 3 parameters (fibrosis stage 3, nondouble wild-type of HCV-CR, and group B) that tended to or significantly influenced hepatocarcinogenesis independently. With regard to hepatocarcinogenesis rates in group C according to HCV-CR and the mean alanine aminotransferase (ALT) during IFN-free period, significantly higher rates were noted in patients of nondouble wild-type with ALT levels of more than 1.5 times the upper limit of normal (25.7%) compared with the others (2.4%). Conclusion: Amino acid substitutions in the HCV-CR are the important predictor of hepatocarcinogenesis. In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1527-3350
|
| pubmed:author |
pubmed-author:AkutaNorioN,
pubmed-author:AraseYasujiY,
pubmed-author:HosakaTetsuyaT,
pubmed-author:IkedaKenjiK,
pubmed-author:KawamuraYusukeY,
pubmed-author:KobayashiMarikoM,
pubmed-author:KobayashiMasahiroM,
pubmed-author:KumadaHiromitsuH,
pubmed-author:SezakiHitomiH,
pubmed-author:SuzukiFumitakaF,
pubmed-author:SuzukiYoshiyukiY,
pubmed-author:YatsujiHiromiH
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1357-64
|
| pubmed:meshHeading |
pubmed-meshheading:17657816-Adolescent,
pubmed-meshheading:17657816-Adult,
pubmed-meshheading:17657816-Alanine Transaminase,
pubmed-meshheading:17657816-Amino Acid Substitution,
pubmed-meshheading:17657816-Antiviral Agents,
pubmed-meshheading:17657816-Carcinoma, Hepatocellular,
pubmed-meshheading:17657816-Female,
pubmed-meshheading:17657816-Follow-Up Studies,
pubmed-meshheading:17657816-Hepacivirus,
pubmed-meshheading:17657816-Hepatitis C, Chronic,
pubmed-meshheading:17657816-Humans,
pubmed-meshheading:17657816-Interferons,
pubmed-meshheading:17657816-Japan,
pubmed-meshheading:17657816-Liver Neoplasms,
pubmed-meshheading:17657816-Male,
pubmed-meshheading:17657816-Middle Aged,
pubmed-meshheading:17657816-Multivariate Analysis,
pubmed-meshheading:17657816-Treatment Outcome,
pubmed-meshheading:17657816-Viral Core Proteins
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
|
| pubmed:affiliation |
Department of Hepatology, Toranomon Hospital, Tokyo, Japan. akuta-gi@umin.ac.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|